Statins for primary prevention: at what coronary risk is safety assured?

• Published in: British journal of clinical pharmacology Vol. 52; no. 4; pp. 439 - 446
• Main Authors: Jackson, Peter R., Wallis, Erica J., Haq, Ifti U., Ramsay, Lawrence E.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Science Ltd 01.10.2001; Blackwell Science; Blackwell Science Inc
• Subjects: Biological and medical sciences; Coronary Disease - etiology; Coronary Disease - mortality; Coronary Disease - prevention & control; drug safety; Female; General and cellular metabolism. Vitamins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; hydroxymethylglutaryl‐Co A reductase inhibitors; hyperlipidaemia; Hyperlipidemias - complications; Hyperlipidemias - drug therapy; Male; Medical sciences; meta‐analysis; Middle Aged; Pharmacoepidemiology; Pharmacology. Drug treatments; Primary Prevention; Randomized Controlled Trials as Topic; Risk Factors; Human; Enzyme; Treatment efficiency; Coronary artery; Enzyme inhibitor; Cardiovascular disease; Controlled therapeutic trial; Coronary heart disease; Thrombosis; Metaanalysis; Arterial disease; Vascular disease; Prevention; Chemotherapy; Treatment; Placebo; Clinical trial; Hydroxymethylglutaryl-CoA reductase; Oxidoreductases; Comparative study; Bibliographic review; Antilipemic agent
• DOI: 10.1046/j.0306-5251.2001.01478.x
• ISSN: 0306-5251

Aims  Increasingly HMG CoA reductase inhibitors (statins) are being used for primary prevention of vascular disease in patients with a raised cholesterol but at low absolute risk of coronary heart disease (CHD). This study uses clinical trial results to explore the limits of absolute safety for statin use in such patients. Methods  The major placebo controlled statin outcome trials were identified by automated and manual literature searches. Principal results including all cause mortality in placebo and intervention groups and baseline values of standard coronary risk factors were ed for each trial. For the trials identified the reduction in overall mortality with statin treatment for each study was regressed against the underlying CHD risk of the population recruited into that trial using a statistically robust method. Results  The regression line describing the relationship between mortality benefit and risk suggests that statin use could be associated with an increase in mortality of 1% in 10 years. This would be sufficiently large to negate statin's beneficial effect on CHD mortality in patients with a CHD event risk less than 13% over 10 years. Conclusions  Absolute safety of statins has not been demonstrated for patients at low risk of CHD. Patients absolute risk of CHD should be calculated before starting statin treatment for primary prevention. Extensions of such treatment to low risk patients should await further evidence of safety.